3US Department of Health and Human Services.Guidance for Industry Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredi-ents[EB/OL].(2001-08)[2011-03-16].http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucml29098.pdf.
4US Department of Health and Human Services.Food and Drug Ad-ministration.Risk-Based Method for Prioritizing cGMP Inspections of Pharmaceutical Manufacturing Sites-A Pilot Risk Ranking Model[EB/ OL].(2004-09)[2011-03-16].http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4080b1_04_risk-based.pdf.
6US Department of Health and Human Services.Food and Drug Administra-tion.Guidance for Industry Quality Systems Approach to Pharmaceutical cGMP Regulations[EB/OL].(2006-09)[2011-03-16].http://www.fda.gov/downloads/Drugs/GuidanceComplianeeRegulatorylnform-ation/Guidances/UCM070337.pdf.
7US Department of Health and Human Services.Food and Drug Administra-tion.Current Good Manufacturing Practice in Manufacturing,Packaging,Labeling.or Holding Operations for DietarySupplements[EB/OL].(2009-01-04)[2011-03-16].http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm.
9Sven P.FDA Issues Draft on cGMP Regulations for"Combination Products"[EB/OL].(2009-10-07)[2010-05-23].http://www.gmp-com-pliance.org/eca_news_1735.html.
10FDA.Focuses On Combination Products With New Proposed Current Good Manufacturing Practices And Adverse Event Reporting Requirements[EB/OL].(2009-10-28)[2011-03-16].http://www.tro-ut-mansanders.com.
5Department of Health and Human Services.U.S. Food and Drug Administration. Pharmaceutical cGMPs for the 21st century: a risk-based approach[J]. J GXP Compliance, 2002,7(1):90-92.
6Department of Health and Human Services.U.S. Food and Drug Administration. Pharmaceutical cGMPs for the 21st century--a risk-based approach: second progress report and implementation plan[J]. J GXP Compliance,2003,8(1):101-111.
7Department of Health and Human Services.U.S. Food and Drug Administration. Pharmaceutical cGMPs for the 21st Century--a risk-based approach (final report)[EB/OL]. http://www. fda. gov/ cder/ gmp/ gmp 2004/GMP finalreport 2004.htm,2004-9-29.
